Summary:
A multicenter, randomized, active-control, phase IIIb study to evaluate the cardiovascular safety of Febuxostat and Allopurinol in subjects with Gout and cardiovascular morbidities.
Qualified Participants Must:
• Be at least 50 years old
• Have experienced a gout flare
• be post menopause (if female)
• have had a heart condition like stroke or diabetes
Qualified Participants May Receive:
Study procedures and labs at no cost; compensation for time and travel